SCHOTT Pharma KGaA Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Andreas Reisse
Chief executive officer
€1.1m
Total compensation
| CEO salary percentage | 34.7% |
| CEO tenure | 2.5yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Nov 25
SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Business Is Trailing The Market But Its Shares Aren't
Oct 27SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Sep 01Is There An Opportunity With SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) 31% Undervaluation?
Aug 07Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts
Jul 01We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
Jun 07Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Mar 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | €1m | €397k | €150m |
| Jun 30 2024 | n/a | n/a | €150m |
| Mar 31 2024 | n/a | n/a | €135m |
| Dec 31 2023 | n/a | n/a | €158m |
| Sep 30 2023 | €839k | €356k | €152m |
| Jun 30 2023 | n/a | n/a | €143m |
| Sep 30 2022 | €793k | €332k | €125m |
Compensation vs Market: Andreas's total compensation ($USD1.18M) is below average for companies of similar size in the German market ($USD2.04M).
Compensation vs Earnings: Andreas's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Andreas Reisse (63 yo)
2.5yrs
Tenure
€1,142,153
Compensation
Mr. Andreas Reisse is Chairperson of Management Board & CEO of SCHOTT Pharma Management AG the GP of SCHOTT Pharma AG & Co. KGaA from July 15, 2022. He studied industrial engineering at the University of K...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman of Supervisory Board | 1.8yrs | €80.00k | no data | |
| Independent Vice Chairman of Supervisory Board | 1.8yrs | €60.00k | no data | |
| Independent Member of Supervisory Board | 1.8yrs | €60.00k | no data | |
| Independent Member of Supervisory Board | 1.8yrs | €50.00k | no data | |
| Employee Representative Member of Supervisory Board | 1.8yrs | €40.00k | no data | |
| Employee Representative Member of Supervisory Board | 1.8yrs | €50.00k | no data |
1.8yrs
Average Tenure
54.5yo
Average Age
Experienced Board: 1SXP's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 19:44 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SCHOTT Pharma AG & Co. KGaA is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Jain | Barclays |
| Victoria Lambert | Berenberg |
| Hugo Solvet | BNP Paribas Exane |